TATACHEM
NSEโ†—BSEโ†—Mid Cap
Tata Chemicals Limited
Chemicalsโ€บChemicals & Petrochemicalsโ€บCommodity Chemicals
Current Priceโ‚น601.95(+0.49%)
Market Capโ‚น15,335 Cr
Analysis WindowQ1 FY27
Last Updated28 Oct 2026
Flagium AI Risk Score
Risk Score measures the severity of detected structural financial risks using Flagium's quantitative risk framework. A lower score indicates fewer or less severe detected risks (0 = Minimal Risk, 100 = Severe Risk). Quarter-to-quarter changes reflect changes in the underlying risk signals, not investment recommendations.
36/ 100
Scale: 0 = Clean โ€ข 100 = Severe Risk (Lower is safer)97th Percentile ยท Sector
Risk ClassWatch
Risk Trend
ImprovingQoQ Delta -20 pts
Business๐ŸŸก Watch
Primary DriverUniversal Inventory Divergence
Valuationsโœ— Demanding
Valuation Score66/100Valuation Risk: High
Market Structureโœ— Weak
Stage 425 sessions

High-quality business currently experiencing weak market structure. Monitor for trend reversal. Valuations remain demanding and supported by current metrics.

Market Alignment๐ŸŸขConfirmingMarket behavior remains consistent with deteriorating financial conditions.

SENTINEL REVIEW

Tata Chemicals Limited (TATACHEM)โ€ขUpdated yesterday

EXECUTIVE FORENSIC DIAGNOSIS
27 Sept 2026

๐Ÿšจ Structural Deterioration Signature: In FY2026, Tata Chemicals Limited is experiencing severe earnings quality deterioration, marked by a 543.2% YoY deterioration in reported net profit, swinging to a net loss of โ‚น1,715 Cr from a profit of โ‚น387 Cr in the prior year. This is compounded by operational friction: expenses outpacing sales, EBIT margins compressing to -5.1% from -1.7% YoY, and a 27.9% drop in operating cash flow to โ‚น1,269 Cr. This operating deterioration is reflected in a persistent negative operating leverage gap of 65.9%, with interest payments consuming most of the profit. Against this liquidity strain, total debt expanded 13.1% to โ‚น8,001 Cr, pushing interest coverage down to 1.86x and entering Flagium's heightened surveillance range. Inventory stress persists, with inventory-revenue divergence signaling potential finished goods accumulation.

WHAT CHANGED THIS QUARTER
  • โœ“Risk score improved (QoQ change: -20 pts)
  • โœ—Profitability margins remain stressed
  • โœ“Inventory Stress resolved this quarter (18 pts)
  • โœ—New risk trigger: Universal Inventory Divergence (+13 pts)
  • โœ—Growth expectations are demanding
  • โœ—Market structure is declining (Stage 4)
  • โœ—Institutional flow regime is Distribution (-0.84ฯƒ)
  • โœ—Share price is down -1.6% this quarter (from โ‚น611.45 on 30 Sept to โ‚น601.95)
DUE DILIGENCE CHECKLIST
  • ๐Ÿ”ดInvestigate Operating Leverage Stress and balance sheet impact
  • ๐ŸŸขMargin Compression resolved in latest filing; verify sustainability in next filing
  • ๐ŸŸขMaintain routine quarterly surveillance; no governance escalation required
RISK CONTRIBUTORS
  • 20.0 ptsBalance Sheet Stress
  • 10.0 ptsGrowth Sustainability
  • 5.5 ptsEarnings Quality
NEED CLARIFICATION ON THIS QUARTER'S AUDIT?

Divergence Radar

BUSINESS STRENGTH64/100
VALUATION ATTRACTIVENESS (MARGIN OF SAFETY)34/100
MARKET TREND STRUCTURE15/100
INSTITUTIONAL FLOW ACCUMULATION29/100

Structural Matrix

Valuation
Business Quality
Attractive
Balanced
Demanding
Strong
Moderate
Weak
๐Ÿ”ด
Profile: MODERATE ร— DEMANDING VALUATION

Risk vs Price Timeline
Visualizing the historical relationship between the structural risk score and stock price movement over time.

Loading Chart
Share Price
Risk Score (0-100)
Market Performance
โ‚น601.95(+0.49%)
1M Divergence+0.53%
DurationPerf.Sector AvgDivergence
1 Week-0.65%-1.46%+0.81%
1 Month-6.16%-6.69%+0.53%
6 Months-24.45%+6.82%-31.27%
1 Year-32.38%+8.93%-41.3%
2 Year-44.22%+47.64%-91.86%
3 Year-35.42%+125.5%-160.91%

Business Analysis Methodology

Business analysis focuses on structural risk inside the company. Flagium monitors earnings quality, balance sheet strength, liquidity, governance, competitive position, and growth sustainability to identify areas where risk may be increasing or decreasing before it becomes obvious in reported results.

Flagium AI Risk Score36 / 100Riskier than 97% of Sector Peers
Risk Class
Watch
Risk Trend-20 QoQ ยท ImprovingRisk score improved (-20 pts)
Stress MomentumStable (0 Qtrs)Consecutive quarters worsening
Severe Risk Chance5%
Low / Manageable
Interpretation

Financial profile remains stable for now. Pressure is receding in balance sheet stress. This suggests the risk profile is currently stabilizing. Risk levels are improving.

Risk Score Composition

Absolute point contribution of each forensic risk driver to the final composite risk score.
Balance Sheet Stress
+20.0 pts
Growth Sustainability
+10.0 pts
Earnings Quality
+5.5 pts
Final Composite Risk36 / 100

Investment Risk Thesis

Historical Trend

Current risk score has risen from 21 โ†’ 36 over 14 quarters.

Expected Direction
IMPROVING TRAJECTORY
Primary Deterioration Drivers
NEWUniversal Inventory Divergence
+13 pts
NEWProfit Collapse
+7.4 pts
ESCOperating Leverage Stress
+3.6 pts
RESOLVEDMargin Compression
-20.2 pts
IMPROVEDLow Interest Coverage
-3.6 pts
What to Watch Next Quarter
  • Inventory turnover
  • Operating profit margins

Risk Drivers (Active Warnings)

Earning Quality
โ– Universal Inventory Divergence
SEVEREAccelerating
โ– Operating Leverage Stress
HIGHPersistent
โ– Profit Collapse
HIGHPersistent
Decaying / Resolved Signals (12Q Surveillance)
โœ“ Margin Compression (Q4-FY26)โœ“ Relative Growth Weakness (Q4-FY26)โœ“ Inventory Stress (Q4-FY26)

Primary Driver & Insights

Key Contributor
Earning Quality
โ– Universal Inventory DivergenceSEVERE
Forensic Analyst Insight

Asset turnover is slowing down due to inventory accumulation. This indicates potential channel stuffing or weaker demand in core product segments.

Advanced Business Analytics

Active Risk Objects (10)Free Preview (2 of 10)

CriticalHigh
[F15]Universal Inventory Divergence
Earnings QualityQuarterlyActive for 1 Qtr
Framework: XBRL Quarterly
Inv DivergenceHigh Tier
+30.6 ppDSI +35.3%
Signal MomentumAccelerating
Historical BaselineStatutory Filing Baseline
Empirical Trigger

TATACHEM: Inventory growth outpaced Revenue growth by +30.6 pp (Inventory holding ratio increased +35.3%).

Forensic Implication

Slight build-up in inventory detected. Monitor for slowing sales momentum.

Statutory XBRLFiling Period: Q1 FY2027
[O1]Operating Leverage Stress
Earnings QualityQuarterlyActive for 3 Qtrs
Framework: XBRL Quarterly
Leverage GapHigh Tier
+65.9%Expense > Rev
Signal MomentumPersistent
Historical Baseline12-Qtr Median: 4.9%
Empirical Trigger

Expenses are consistently growing faster than revenues, creating operational pressure.

Forensic Implication

Margins are in freefall. Operating costs are growing significantly faster than revenue.

Statutory XBRLFiling Period: Q1 FY2027
๐Ÿ”’
โญ Pro Forensic Intelligence

Unlock All 10 Forensic Signals (8 Additional Warnings Gated)

Free accounts preview the top 2 highest-impact warning signals. Upgrade to Flagium Pro to inspect all 10 active forensic detectors, multi-quarter duration streaks, and financial stress metrics for Tata Chemicals Limited.

Unlock with Pro Free โ†’๐ŸŽ 3-Month Free Trial Available

Statutory Note: Forensic signals are algorithmic quantitative observations derived from publicly filed XBRL disclosures and do not constitute allegations of legal misconduct or investment recommendations.

Unlock Interactive Signal Evidence Dossier

Access complete multi-quarter financial evidence, 5-KPI snapshot strips, diagnostic hypotheses, and 1-page forensic PDF dossiers for Tata Chemicals Limited.

Upgrade to PROView All Plans
Risk Trajectory
Historical 12-quarter risk trend (Q-11 to Q0) followed by a 2-quarter predictive funnel (Q+1, Q+2).
Loading Chart
Business Stability
Key indicators of structural risk, cash buffer capability, and risk progression.
Shock ResistanceLow
Severe Risk ChanceLow
Financial StabilityHigh
Margin of SafetyHigh
Forensic Benchmark Context: Chemicals (n=129 peers)

Structural Risk Attribution

Auditable forensic risk attribution explaining why the Flagium AI Risk Score changed between quarters. Deconstructs the score delta into new triggers, severity escalations, cross-pillar contagion overlays, and rules no longer triggered in the latest quarter.

Deterministic quarter-on-quarter causal decomposition grounded in statutory exchange filings.

Peer Benchmark:Chemicals(n=129 peers)
Median Risk: 19/100Position: 97th Percentile

Historical Trajectory (12Q)

โ† Swipe older12Q window
5/100
Base
6/100
11/100
7/100
6/100
11/100
36/100
BREAK
31/100
31/100
31/100
56/100
36/100
RECOVERYLATEST
56โž”36/100
โ–ผ20-point improvement(Q4 FY26 โž” Q1 FY27)
Structural Recovery Quarter
Auditable forensic risk attribution explaining why the Flagium AI Risk Score changed between quarters.
Executive Synthesis:

Risk improved materially (-20.0 pts), driven by Margin Compression (-20.2 pts) and Inventory Stress (-18.0 pts), partially offset by new Universal Inventory Divergence (+13.0 pts) and new Profit Collapse (+7.4 pts).

Reconciliation Bridgeยท Swipe โž”
Deterministic Statutory Flow
Base56Q4 FY26
โž”
+ New Stress+243 flags
โž”
- Resolved-63.25 flags cleared
โž”
Scaling & Drift
Net calibration combining economic pillar capacity ceiling (+19.2 pts) and temporal volatility dampening (0 pts).
+19.2Pillar Cap & Drift
โž”
Terminal36-20 net ยท Q1 FY27
What Changed This Quarter8 Active Catalysts
New Stress (2 Flags)
+13 pts
Balance Sheet StressยทSEVERE Risk
โ€ข Trigger:Inventory accumulated faster than sales throughput, signalling working capital lockup.
Revenue YoY:+13.0%
+7.4 pts
Earnings QualityยทHIGH Risk
โ€ข Trigger:Net profit experienced severe contraction, triggering earnings distress alert.
PAT YoY:-81.0%
Escalated Stress (1 Flag)
+3.6 pts
Growth SustainabilityยทEscalated Risk
โ€ข Trigger:Operating expense growth outpaced revenue growth, breaching operating leverage stress threshold.
Revenue YoY:+13.0%Op. Expenses YoY:+19.6%Operating Margin:-5.1% โ†’ 2.9%
Normalized & Resolved (5 Flags)
-20.2 pts
Earnings QualityยทBelow Risk Threshold
โ€ข Cause:Operating margins stabilized or expanded, easing profitability compression below risk threshold.
Operating Margin:-5.1% โ†’ 2.9%Revenue YoY:+13.0%
-18 pts
Growth SustainabilityยทBelow Risk Threshold
โ€ข Cause:Inventory turnover normalized with stock levels realigning to sales velocity.
Revenue YoY:+13.0%
-15.8 pts
Competitive PositionยทBelow Risk Threshold
โ€ข Cause:Underlying risk metrics normalized below Flagium's systematic alert threshold.
Revenue YoY:+13.0%PAT YoY:-81.0%
-5.6 pts
Balance Sheet StressยทBelow Risk Threshold
โ€ข Cause:Trade debtor collections accelerated, reducing receivables-to-revenue divergence.
Revenue YoY:+13.0%
-3.6 pts
Balance Sheet StressยทBelow Risk Threshold
โ€ข Cause:Operating earnings expanded relative to finance costs, lifting debt service coverage.
Interest Coverage:-1.2x โ†’ 0.9x
Risk Pillar Changes
Net shift in risk score points contributed by each fundamental economic pillar between the two quarters.
6 Fundamental Pillars
Balance Sheet Stress+3.8 pts
Q4 FY26: 16.2โ†’Q1 FY27: 20
Competitive Position-15 pts
Q4 FY26: 15โ†’Q1 FY27: 0
Earnings Quality-9.5 pts
Q4 FY26: 15โ†’Q1 FY27: 5.5
Governanceโ€”
Q4 FY26: 0โ†’Q1 FY27: 0
Growth Sustainabilityโ€”
Q4 FY26: 10โ†’Q1 FY27: 10
Solvencyโ€”
Q4 FY26: 0โ†’Q1 FY27: 0

12Q Structural Regimes & Inflections

Deterministic macro trajectory milestones
STRUCTURAL BREAK โ€” Q4 FY2511 โ†’ 36 | +25 pts

Risk deteriorated materially (+25.0 pts), driven by new Margin Compression (+16.2 pts) and new Inventory Stress (+14.4 pts), partially offset by Profit Collapse relief (-10.6 pts).

Forensic Trajectory Shifts:
โ€ขNew Forensic Triggers: 3 new risk signals emerged: Margin Compression, Inventory Stress, Working Capital Expansion
โ€ขOperating Margin: 0.9% โ†’ -1.7%
โ€ขRevenue YoY: -1.1%
โ€ขInventory YoY: +1.3%
STRUCTURAL RECOVERY โ€” Q1 FY2756 โ†’ 36 | -20 pts

Risk improved materially (-20.0 pts), driven by Margin Compression (-20.2 pts) and Inventory Stress (-18.0 pts), partially offset by new Universal Inventory Divergence (+13.0 pts) and new Profit Collapse (+7.4 pts).

Recovery Trajectory Shifts:
โ€ขResolved Forensic Flags: 4 risk signals extinguished: Margin Compression, Inventory Stress, Relative Growth Weakness
โ€ขLow Interest Coverage De-escalation: Severity reduced from HIGH to MEDIUM
โ€ขInterest Coverage: -1.2x โ†’ 0.9x
โ€ขOperating Margin: -5.1% โ†’ 2.9%

Business Resilience & Benchmark Context

Overall: HEALTHY
Solvency(10)Excellentโ˜…โ˜…โ˜…โ˜…โ˜…
โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ100th %ile
Governance(10)Excellentโ˜…โ˜…โ˜…โ˜…โ˜…
โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ100th %ile
Earnings Quality(6.3)Fairโ˜…โ˜…โ˜…โ˜†โ˜†
โ–ˆโ–ˆโ–ˆโ–‘โ–‘63th %ile
Balance Sheet Stress(0)Weakโ˜…โ˜†โ˜†โ˜†โ˜†
โ–‘โ–‘โ–‘โ–‘โ–‘0th %ile
Competitive Position(10)Excellentโ˜…โ˜…โ˜…โ˜…โ˜…
โ–ˆโ–ˆโ–ˆโ–ˆโ–ˆ100th %ile
Growth Sustainability(0)Weakโ˜…โ˜†โ˜†โ˜†โ˜†
โ–‘โ–‘โ–‘โ–‘โ–‘0th %ile

PEER COMPARISON MATRIX

Ranked surveillance & credit risk comparison against sector peers

Company displays higher risk profile compared to the Sector Mean (19).
AETHERLowest Risk
Aether Industries Limited
0STABLE
Sector %ile0th
Delta-5
Active Flags16
Accel+0
Growth Sustainability

Stable

AARTISURF
Aarti Surfactants Limited
11WATCH
Sector %ile30th
Delta-5
Active Flags18
Accel+0
Growth Sustainability

Stable

AARTIIND
Aarti Industries Limited
13WATCH
Sector %ile32th
Delta-7
Active Flags26
Accel+0
Balance Sheet Stress

Stable

ADVANCE
Advance Agrolife Limited
13WATCH
Sector %ile32th
Delta+2
Active Flags4
Accel+2
Balance Sheet Stress

Stable

ACIHighest Risk
Archean Chemical Industries Limited
31MODERATE
Sector %ile84th
Delta-5
Active Flags23
Accel+0
Growth Sustainability

Watch

TATACHEM
Tata Chemicals Limited
36MODERATE
Sector %ile97th
Delta-20
Active Flags10
Accel+0
Balance Sheet Stress

Watch

* Peer comparison is based on risk signals, not valuation or returns.

Unlock 5-Year Forensic Divergence Cockpit

Access multi-year visual divergence charts (EBITDA vs CFO Cash Gap, Receivables Decoupling Spread, and Debt vs FCF Burn) for Tata Chemicals Limited.

Upgrade to PROView All Plans

FINANCIAL STATEMENTS

Financial SummaryAudited ยท Consolidated
Operating Margin (OPM)
1.1%
Weakeningโ†“
Cash Conversion (CCC)
63 Days
Weakeningโ†“
Debt / Equity Ratio
0.36x
Deterioratingโ†‘
Revenue Trend
โ‚น14,900 Cr
Weakeningโ†“
Swipe for all periods โ‡†
MetricFY2026FY2025FY2024FY2023FY20223Y CAGR
Structural triggersโ€“โ€“โ€“
Revenue14,90015,11215,70717,00712,878-4%
growth % YoYโˆ’1.4%โˆ’3.8%โˆ’7.6%+32.1%โ€”โ€”
EBITDA1652,0532,2724,0402,550-66%
margin %1.1%13.6%14.5%23.8%19.8%โ€”
Net Profit(1,715)3874352,4341,405n/m
margin %-11.5%2.6%2.8%14.3%10.9%โ€”
CFO1,2691,7613,0162,9711,644-25%
CFO / Net Profit-0.74x4.55x6.93x1.22x1.17xโ€”
Debt8,0017,0725,5636,296โ€”+8%
Structural triggers first appear in FY2025 (ringed).

Working Capital & Forensic Monitor

Operating Cycle Disclosuresยท10 Fiscal Years

Forensic Accounting Signals:Inventoryโ€“Revenue Divergence: +21.9 pp (Monitor inventory turnover & carrying costs)
Cash Conversion Cycle
63 days+16d YoY
Receivables:+5d
Inventory:+13d
Payables:+2d
Net Working Capital
โ‚น2,618 Cr
5-Year Average Cycle: 53 days
Earnings-to-Cash Divergence
โ‚น-2,984 Cr
PAT โˆ’ CFO (Cash Surplus)
5Y Cum: โ‚น-7,715 Cr
Accrual Quality Monitor
Clean (Cash Backed)
Accruals: -7.77% of Avg Assets

Working Capital Schedule (INR Cr)

Metric / RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Trade Receivables(โ‚น Cr)
2,0881,9001,9002,627โ€”โ€”โ€”โ€”โ€”โ€”
Inventories(โ‚น Cr)
3,0822,5582,5242,532โ€”โ€”โ€”โ€”โ€”โ€”
Trade Payables(โ‚น Cr)
2,5522,5102,3692,597โ€”โ€”โ€”โ€”โ€”โ€”
Net Working Capital(โ‚น Cr)
2,6181,9482,0552,562โ€”โ€”โ€”โ€”โ€”โ€”
Working Capital / Sales(%)
17.6%12.9%13.1%15.1%โ€”โ€”โ€”โ€”โ€”โ€”

Cash Conversion & Operating Cycle (Days)

Metric / RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Cash Conversion Cycle (CCC)(days)
63d47d48d54dโ€”โ€”โ€”โ€”โ€”โ€”
Debtor Days (DSO)(days)
51d46d44d56dโ€”โ€”โ€”โ€”โ€”โ€”
Inventory Days (DIO)(days)
75d62d59d54dโ€”โ€”โ€”โ€”โ€”โ€”
Creditor Days (DPO)(days)
63d61d55d56dโ€”โ€”โ€”โ€”โ€”โ€”

Forensic Accounting Monitor & Divergences

Metric / RatioFY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017
Receivable Growth vs Sales (ฮ”)(%)
+11.3%+3.8%-20.0%โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Inventory Growth vs Sales (ฮ”)(%)
+21.9%+5.1%+7.3%โ€”โ€”โ€”โ€”โ€”โ€”โ€”
Asset Growth vs Sales (ฮ”)(%)
+4.7%+6.6%+12.4%โ€”โ€”โ€”โ€”โ€”+10.4%โ€”
Earnings-to-Cash Divergence (PAT - CFO)(โ‚น Cr)
-2,984-1,374-2,581-537-239โ€”โ€”โ€”832-2,297
Accrual Ratio (Accruals / Avg Assets)(%)
-7.8%-3.7%-7.2%-1.5%โ€”โ€”โ€”โ€”3.4%-9.7%
Operating Cash Realisation (CFO / EBITDA)(%)
384.5%357.9%185.8%108.4%113.3%โ€”โ€”โ€”55.9%168.4%
Capitalisation Intensity (CWIP / Assets)(%)
โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”โ€”

Industry Intelligence

Chemicals KPIs
Gross Margin
โ“˜
Q1 FY2027
Current79.4%
QoQ Change-80 bpsโ†“ Profitability contraction
YoY Change+110 bpsโ†‘ Operating efficiency gains
Industry Median48.5%
EBITDA Margin
โ“˜
Q1 FY2027
Current14.2%
QoQ Changeโ€”
YoY Change-530 bpsโ†“ Profitability contraction
Industry Median15.5%
Asset Turnover
โ“˜
Q1 FY2027
Current0.11x
QoQ Change+22.2%โ†‘ Asset efficiency accelerating
YoY Change+10.0%โ†‘ Asset efficiency accelerating
Industry Median1.15x

Understanding Chemicals KPIs

Gross Margin: Revenue minus cost of materials as % of revenue. Measures pricing power. Learn More โ†’
EBITDA Margin: EBITDA divided by revenue. Core operational profitability metric. Learn More โ†’
Asset Turnover: Revenue generated per rupee of asset base. Measures asset efficiency. Learn More โ†’
Shareholding Pattern & Pledging Monitor12QZero Pledge
Ownership structure stable
Promoter holding 37.98% unchanged across 12 quarters ยท zero pledge or encumbrance ยท institutional holding 31.35%
Q2 FY2027 ยท latest disclosed quarter
Net Capital Flow (Q2 FY2027):FII -0.37 ppDII -1.47 ppPromoters 0 ppPublic +1.83 pp
FII+DII Net: -1.84 pp
Latest Ownership Distribution (Q2 FY2027)100.00%
Promoters (37.98%)
FII (11.70%)
DII (19.65%)
Govt (0.03%)
Public (30.64%)
Quarterly Progression
4 unchanged โ€” Promoters 37.98% ยท Government 0.03% ยท Promoter Pledge (% Prom) 0.00% ยท Total Pledged (% Eq) 0.00% across 12 quarters

* Sourced from quarterly shareholding pattern disclosures filed under Regulation 31 of SEBI (LODR) Regulations. Pledged shares include encumbrances, non-disposal undertakings (NDU), and liens.

๐ŸŽ™๏ธ

Concall & Management Takeaways

Investor Earnings Call Transcripts & Tone Analysis

No investor earnings call transcripts transcribed for this scrip.

Earnings call intelligence is automatically populated when companies conduct quarterly earnings calls with institutional investors and publish transcripts.

Sentinel Forensic AssessmentALGORITHMIC RISK PROFILE โ€ข NON-ADVISORY
Fundamental Status

Business quality remains stable.

Forensic Pressure

Current forensic pressure is elevated and improving.

Primary Risk Vectors

Key risks remain concentrated in growth sustainability and operating leverage.

The risk profile is Early Signals and currently improving. Recent structural triggers in balance sheet stress suggest a building pressure on the underlying framework. Material forensic traces are visible in core structural metrics, indicating a progressive erosion of structural stability. Initial structural recovery is visible; monitor for a sustained return to resilience.

Market Expectation Engine

DEMANDING EXPECTATIONS

Investor Translation โ€ข What the market price is expecting

Expectation Engine

At the current price of โ‚น602, the market expects this company to grow its net profits by 74.5% every year for the next 5 years. If you think the company will grow faster than 74.5%, current market prices reflect a discount relative to that growth assumption.

Sentinel Takeaway:The market expects future growth significantly above the company's historical delivery. Current market expectations appear demanding relative to the business's track record, resulting in higher expectation risk.

Market-Implied Growth74.5%Future Growth Needed
Historical Delivery-31.0%Actual Past Growth
Expectation Gap+105.5%Growth Jump Needed
Expectation Risk66/100Price Risk Score
CONSERVATIVE (-33%)BALANCEDDEMANDING (76%)
Historical (-31.0%)
Market (74.5%)
Valuation Summary

Using the Discounted Cash Flow (DCF) model, the market is pricing TATACHEM for 74.5% long-term growth versus -31.0% historical delivery. Current expectations appear demanding, and historical fundamentals provide limited support.

Business Delivery Capacity

Performance quality vs historical benchmarks
Historical Delivery Assessment
Revenue Growth SupportObserved CAGR vs cost of capital baseline
-31.0% CAGR
โœ— Weak
Operating Profitability SupportEBIT margins compared to historical standards
5.3% Margin
โœ— Weak Margin
Cash Flow Generation SupportOperating cash flow conversion and support cushion
14.2% Conv
โœ“ Positive
Capital Leverage RiskLeverage indicators and solvency pressure
Pressure
โœ— Leverage Risk
Delivery Capacity Index
30/100
LOW CAPACITY

Historical business performance currently provides limited support for the market's implied growth assumptions. Improvement in revenue growth and operating efficiency would strengthen expectation support.

WHY IS EXPECTATION RISK ELEVATED?

Risk Drivers:
โœ“High implied growth
โœ“Weak historical delivery
โœ“Expensive valuation regime
โœ“Weak profitability support

Valuation Context

Historical Valuation59th percentile
Cash Yield Support0.42% (Weak)
Sector Premium+4693% EV/EBITDA
Current Valuation RegimeDemanding

WHAT MUST HAPPEN FOR CURRENT PRICE TO BE CORRECT?

MARKET REQUIRED METRICS
Assumption MetricRequired (To justify current price)Historical Delivery (Average)Fulfillment Assessment
Revenue Growth (CAGR)74.5%-31.0%Aggressive
Operating Margin (EBIT)0.9%5.3%Achievable
Free Cash Flow Conversion46.0%14.2%Aggressive

*Required metrics indicate the operating efficiency and revenue expansion parameters that must be sustained long-term to justify the current stock price.

Advanced Valuation Analytics
Sentinel Expectation Assessment

The current valuation assumes business performance well above the company's historical record. Historical operating performance currently provides limited evidence that these expectations are sustainable. Continued revenue acceleration and stronger profitability would be required to justify current pricing.

Market Structure Methodology

Flagium separates Business Risk from Market Structure. Business analysis explains what is happening inside the company. Market Structure measures how investors are behaving through price trends, momentum, participation, and institutional activity. Divergences between the two often reveal important transitions before they become obvious.

Market Structure
STAGE 4
DOWNTRENDCAPITAL EROSION RISK
Stage Progress
Measures the progress of the stock's current price, volume, and momentum characteristic alignments.
0%
TrendDeclining
MomentumNeutral
ParticipationNeutral
A/D FlowDeteriorating
Sentinel Market Insight

The stock remains in a confirmed Stage 4 declining phase. Institutional participation has also deteriorated, compounding the weak trend as momentum continues to deteriorate. Current price action does not yet confirm a structural recovery.

What Is Driving Market Structure?

Market Drivers
โœ—Long-term trend remains below the 150DMA
โœ—Long-term trend remains below the 200DMA
โœ—RS continues to lag the market
โœ—Institutional flow has deteriorated
โœ—Momentum remains negative
Summary
๐ŸŸขConfirming

Market behavior remains consistent with deteriorating financial conditions.

Market Cycle Stage Analysis

Stan Weinstein 4-Stage Cycle
S1
Base Building(Institutional accumulation & base building)
S2
Strong Uptrend(Ideal breakout & momentum zone)
S3
Topping Out(Institutional distribution & profit taking)
S4
Downtrend(Elevated capital erosion risk)
Stage Lifecycle
Stage Progress
0%
Readiness LabelLow (Early Base Consolidation)
Regime Sessions25 Sessions
Transition Probability0% Low
Measures the alignment and consistency of the stock's price trend relative to its historical volume volatility.
2.4409ฯƒ Healthy
Trend & Strength
Trend QualityDeteriorating
150 DMA Slope-1.3105%
Participation & Volume
Total rupee value of shares actually delivered into buyers' Demat accounts today (excluding intraday trades). Delivery % indicates what portion of today's total trade was held as delivery rather than squared off intraday.
โ‚น7.8 Cr27.06% Delivery (Day-Trading Heavy)
Compares the 21-day average delivery turnover against the 200-day long-term baseline. Delivery expansion above baseline confirms a structural accumulation trend.
โ–ผ 6.4% (21D vs 200D Avg)Steady Baseline Delivery
Avg Turnover (200D)
The 200-day average daily traded turnover in โ‚น Crore. Represents baseline trading depth and capacity to enter or exit positions with minimal slippage.
โ‚น100.7 Cr
Liquidity Rating
Categorizes trading liquidity based on 200-day average turnover: Liquid (โ‰ฅโ‚น100 Cr/day), Low Liquidity (โ‚น50โ€“โ‚น100 Cr/day), or Illiquid (<โ‚น50 Cr/day) for sizing and slippage risk control.
Liquid
Participation
Evaluates current volume participation against historical baseline turnover. Healthy (โ‰ฅ1.2x) confirms active broad-market sponsorship, while Weak (<0.8x) indicates lack of volume conviction.
Healthy

Momentum & Institutional Flow

Price Momentum
Momentum StrengthWeakening momentum trend
Price momentum score in standard deviations (ฯƒ). Readings beyond ยฑ2.0ฯƒ indicate extreme momentum shifts.
-0.2341ฯƒ
Universe Rank
#1398 of 2259Bottom 38.11% in momentum strength
Institutional Accumulation
21D Flow Score
21-day cumulative institutional flow score in standard deviations (ฯƒ).
-0.84ฯƒ
7D Flow TrendDeteriorating
TATACHEM
STAGE 4 โ€ข DECLINE
โ€”
C:โ€”
Loading Market Structure Data...

Methodology & Regulatory Disclaimer

Flagium AI is an automated financial data analytics and research platform providing quantitative risk, forensic, and valuation analytics for informational and educational purposes only. Flagium AI is not registered with SEBI as a Research Analyst or Investment Adviser under SEBI regulations. These analytics do not constitute financial planning, investment advice, or recommendations to buy, sell, or hold any security.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing. Please consult a SEBI-registered Investment Adviser before acting on any data presented.

๐Ÿ“ฌ Flagium Risk Brief โ€” Track forensic risks on TATACHEM & 3 market anomalies weekly

See a sample issue โ†’